Private hospital costs in Australia continue to climb while Medicare rebates cover an increasingly shrinking share. This guide compares what Australians actually pay privately against published JCI-accredited Chinese hospital prices — giving you the numbers you need before deciding.
Updated August 2026. If you live in Australia and have tried to navigate private healthcare costs, you've likely noticed a pattern: premiums go up every year, gap payments grow, and the Medicare rebate covers less than half of what specialists actually charge. When you factor in hospital facility fees, anaesthetist charges, and allied services, a single procedure can run into tens of thousands of dollars.
China has become an increasingly popular destination for Australians seeking affordable, high-quality care — driven not just by price but by access to advanced therapies unavailable through the TGA, shorter waits, and world-class facilities in cities close enough to reach in under a day's flight. Here's the full comparison.
Australia operates a hybrid system — Medicare provides free public care, but publicly-funded waitlists for elective procedures regularly exceed six months. Private health insurance helps, but the economics are shifting:
Note: These figures are approximate ranges drawn from publicly available Australian private-hospital pricing guides (e.g., Raine Hospital Group, Epworth, St George Private). Individual quotes vary significantly based on surgeon fees, complications, length of stay, and other factors. China prices below come from published hospital pricing sheets collected 2025–2026.
This table shows typical Australian private-sector prices compared against the published all-in cost ranges from our partner hospitals in China. Every China figure comes from verifiable hospital pricing collected in 2025–2026.
| Treatment | Australia private (approx.) | China all-in | Savings |
|---|---|---|---|
| Cancer — CAR-T cell therapy | AU$650,000+ | $89,000–170,000 | ~70% |
| Cancer — Immunotherapy (per year) | AU$200,000–350,000 | $25,000–45,000 | ~80% |
| Knee replacement | ~$9,500–19,000 | ~$6,000–8,000 | ~50–60% |
| Hip replacement | ~$11,500–22,500 | ~$8,000–12,000 | ~50–60% |
| Cardiac bypass | ~$19,000–51,000 | $10,000–18,000 | ~50–65% |
| Executive health checkup | ~$1,300–3,800 | $1,000–5,000 | ~10–50% |
| IVF (per cycle) | ~$5,100–9,600 | $4,000–6,000 | ~20–40% |
| Diagnostics (PET-CT, biopsy panels) | ~$3,200–9,600 | $1,500–4,000 | ~50–60% |
These China figures are consistent with those published on our cancer treatment cost guide and US vs China comparison — sourced from the same published hospital price lists.
Australia's costs reflect a smaller, geographically-isolated market with fewer competing providers per capita and higher operating costs for hospitals (labour, facilities, equipment maintenance). China, by contrast, operates massive-volume public teaching hospitals whose economies of scale allow them to deliver comparable clinical outcomes at dramatically lower unit costs. JCI-accredited facilities in China use identical imaging platforms (Siemens, GE, Philips), employ surgeons trained at institutions including PUMCH and Ruijin, and follow internationally-standard clinical protocols.
Beyond cost, there are specific treatments that Australian patients access through China because they haven't received TGA approval locally. The Hainan Boao Lecheng International Medical Tourism Pilot Zone is key here — it permits licensed hospitals in the zone to provide imported drugs and devices that are already FDA-approved or EMA-approved, without waiting for TGA registration. This means:
Despite being thousands of kilometres from Australia, China is logistically very manageable:
The unlicensed broker problem exists globally — and Australian patients searching online for "medical tourism Asia" encounters agencies requesting AUD $10,000–$50,000 upfront with no refund mechanism. Our escrow structure eliminates this entirely:
For Medicare-covered procedures, the public system offers free treatment but with potentially long wait times. Private costs involve a gap payment above the Medicare schedule fee, which can range from $2,000 to $50,000+ depending on procedure complexity. Complex surgeries like bypass or joint replacement routinely exceed AU$30,000–AU$80,000 in the private sector.
Most Australian private health insurance policies offer limited or no overseas treatment coverage. Some international add-ons exist but are expensive and often impose caps well below actual treatment costs in the West. Even where coverage exists, coordinating cross-border billing is difficult. Paying out-of-pocket in China through our escrow structure typically costs less than Australian private-hospital self-pay rates.
Very practical. Sydney-Melbourne-Beijing/Shanghai flights are 9–11 hours. China's visa-on-arrival policy for many nationalities and the Hainan visa-free entry for citizens of 86 countries make logistics straightforward. Our coordinators handle flights, hotel, airport transfers, and in-country translation.
The Hainan Boao Lecheng Pilot Zone grants access to therapies approved by FDA or EMA but not yet registered in Australia (TGA). This includes certain CAR-T products, advanced immunotherapies, and stem cell programs that may be years away from Australian approval. Mainland JCI-accredited centers also carry larger volumes of specialized procedures like proton therapy and robotic-assisted oncologic surgery.
Many Australian patients choose to combine recovery time with short cultural trips — Shanghai, Guilin, Xi'an, and Beijing are popular extensions. We don't organize tourism but are happy to point you toward resources once your treatment schedule is confirmed.
Attach your diagnosis. We'll respond within one business day.